Cibus (CBUS) announced that two of its disease resistance trait products under development for canola have been designated as being not regulated by the United States Department of Agriculture’s Animal and Plant Health Inspection Service, USDA-APHIS, Biotechnology Regulatory Services, BRS. The two trait products reviewed by USDA-APHIS were developed utilizing Cibus’ Rapid Trait Development System, RDTS, technologies that enable targeted genetic changes without integrating recombinant DNA – foreign genetic material – at any stage in the crop’s development. As a result of this designation, USDA-APHIS has confirmed the plants do not meet the definition of a “regulated article” under 7 CFR Part 340, which enables Cibus to proceed with product development without restrictions associated with regulated articles in the U.S.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBUS:
- Cibus’s Strong Revenue Growth and Strategic Realignment Drive Buy Rating Amid EU Regulatory Progress
- Cibus negotiations with EU moving forward is significant, says Canaccord
- Cibus, Inc. Earnings Call: Strategic Progress Amid Challenges
- Cibus’s Growth Potential and Market Expansion: A Buy Rating by Amit Dayal
- Cibus, Inc. Reports Progress in Gene Editing and Financial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue